Literature DB >> 16466828

Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.

Ronit Shiri-Sverdlov1, Kristiaan Wouters, Patrick J van Gorp, Marion J Gijbels, Benoit Noel, Laurent Buffat, Bart Staels, Nobuyo Maeda, Marc van Bilsen, Marten H Hofker.   

Abstract

BACKGROUND/AIMS: The molecular mechanisms leading to Non-Alcoholic Steatohepatitis (NASH) are not fully understood. In mice, NASH can be inhibited by fenofibrate, a synthetic agonist for the nuclear receptor peroxisome proliferator activated receptor alpha, which regulates hepatic triglyceride metabolism. This study aimed to elucidate the relation between steatosis and inflammation in NASH in a human-like hyperlipidemic mouse model.
METHODS: Liver phenotype and gene expression were assessed in APOE2 knock-in mice that were fed a western-type high fat diet with or without co-administration of fenofibrate.
RESULTS: In response to a western diet, APOE2 knock-in mice developed NASH characterized by steatosis and inflammation. Strikingly, macrophage accumulation in the liver preceded the steatosis during progression of the disease. This phenotype was in line with gene expression patterns, which showed regulation of two major groups of genes, i.e. inflammatory and lipid genes. Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis. Moreover, a marked reduction in the expression of inflammatory genes occurred immediately after fenofibrate treatment.
CONCLUSIONS: These data indicate that inflammation might play an instrumental role during the development of NASH in this mouse model. Inhibition of NASH by fenofibrate may be due, at least in part, to its inhibitory effect on pro-inflammatory genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16466828     DOI: 10.1016/j.jhep.2005.10.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  63 in total

1.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

2.  Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

Authors:  Silvia Bijland; Elsbet J Pieterman; Annemarie C E Maas; José W A van der Hoorn; Marjan J van Erk; Jan B van Klinken; Louis M Havekes; Ko Willems van Dijk; Hans M G Princen; Patrick C N Rensen
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 3.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

4.  Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.

Authors:  Sally Yu Shi; Rubén García Martin; Robin E Duncan; Diana Choi; Shun-Yan Lu; Stephanie A Schroer; Erica P Cai; Cynthia T Luk; Kathryn E Hopperton; Anthony F Domenichiello; Christine Tang; Mark Naples; Mark J Dekker; Adria Giacca; Khosrow Adeli; Kay-Uwe Wagner; Richard P Bazinet; Minna Woo
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

5.  PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB.

Authors:  Nadia Bougarne; Réjane Paumelle; Sandrine Caron; Nathalie Hennuyer; Roxane Mansouri; Philippe Gervois; Bart Staels; Guy Haegeman; Karolien De Bosscher
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-17       Impact factor: 11.205

6.  Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.

Authors:  Vanessa Souza-Mello
Journal:  World J Hepatol       Date:  2015-05-18

7.  In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM.

Authors:  Jun-ichi Takino; Kentaro Nagamine; Masayoshi Takeuchi; Takamitsu Hori
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

8.  Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability.

Authors:  Sergio Perez-Diaz; Lance A Johnson; Robert M DeKroon; Jose M Moreno-Navarrete; Oscar Alzate; Jose M Fernandez-Real; Nobuyo Maeda; Jose M Arbones-Mainar
Journal:  FASEB J       Date:  2014-05-08       Impact factor: 5.191

Review 9.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

10.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.